US-based Mylan has signed an agreement with Famy Care, a global, India-based manufacturer of women's health care products, to develop and supply 22 oral contraceptive medicines to customers in the US.
Subscribe to our email newsletter
The agreement also provides Mylan with a right of first refusal for additional oral contraceptive products and certain additional markets, including Australia and Japan, where Mylan has a significant presence.
Robert Coury, vice chairman and CEO of Mylan, said: “Through our partnership with Famy Care, we have met another longstanding commitment by expanding our portfolio to create a women’s health care franchise for Mylan.
“We anticipate filing abbreviated new drug applications as early as the next few months and beginning to commercialize them in 2010.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.